Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...
Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...
Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...
Several months into a multiyear quest to “rigorously prioritize” its pipeline, Takeda is cutting a handful of ...
Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...
Define Ventures identifies about 20 health tech startups, including Innovaccer, Hinge Health & Devoted Health that are poised ...
A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...
Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.
Sanofi CFO François Roger signals increased M&A activity, eyes China for innovation, as company expects cash from Opella sale ...
API maker Bright Green plans $3.5B US facilities; EU launches biotech hub; Q4 earnings from Thermo Fisher, Sartorius, Danaher; Piramal reports growth; Upperton completes UK site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback